# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Andrew Fein reiterates I-MAB (NASDAQ:IMAB) with a Buy and maintains $8 price target.
Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising...
HC Wainwright & Co. analyst Andrew Fein reiterates I-MAB (NASDAQ:IMAB) with a Buy and maintains $8 price target.
I-Mab (NASDAQ:IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the ...
The collaboration will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody join...